nanotech investing Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
nanotech investing PRAME-directed Cell Therapy Using Immatics' TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
nanotech investing Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
nanotech investing Immatics Highlights Compelling Anti-Tumor Activity of Anzu-cel PRAME Cell Therapy in Metastatic Uveal Melanoma at the ESMO 2025 Presidential Symposium
VVC Exploration Corporation Announces Application For Management Cease Trade Order And Provides Financing Update
